SAME-DAY FULFILLMENT  ·  SHIPS FREE OVER $200  ·  SECURE CREDIT CARD CHECKOUT
Research Library
Research

FOXO4-DRI: Senolytic Peptide — Research Overview

FOXO4-DRI is a D-retro-inverso synthetic peptide derived from the FOXO4 transcription factor's p53-interacting domain, designed to disrupt the FOXO4-p53 protein-protein interaction in senescent cells.

Identity and sequence

FOXO4-DRI is a D-retro-inverso synthetic peptide derived from a FOXO4 region involved in interaction with p53. It was designed to disrupt that protein interaction in senescent-cell research.

Originating model and mechanism

Baar et al. (2017) reported disruption of FOXO4–p53 interaction, p53 redistribution and apoptosis in the tested senescent-cell systems, with additional experiments in chemotoxicity and aging mouse models. Selectivity is an observation within those experiments, not a universal guarantee of sparing other cells.

Subsequent primary studies

Huang et al. (2021) investigated FOXO4-DRI in expanded human chondrocyte cultures. Kong et al. (2025) studied senescent keloid fibroblasts and p53-serine-15 phosphorylation/nuclear localization. Human-derived cells are not human clinical trials.

Tripathi et al. (2021) developed a distinct senolytic approach targeting the FOXO4–p53 complex. It supplies related mechanistic context and must not be presented as an experiment proving the exact FOXO4-DRI preparation’s activity.

Limitations and product evidence

These cell and rodent findings do not establish broad anti-aging effects or human treatment efficacy. The labeled 10 mg product requires independent identity and lot evidence. This article does not convert preclinical findings into a use or dosing recommendation.

Related

References

  1. Baar MP et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. [primary; senescent-cell experiments and mouse models]PMID: 28340339DOI: 10.1016/j.cell.2017.02.031
  2. Huang Y et al. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. [primary; expanded human chondrocyte cultures]PMID: 33996787DOI: 10.3389/fbioe.2021.677576
  3. Tripathi U et al. (2021). Development of a novel senolytic by precise disruption of FOXO4-p53 complex. [primary; distinct FOXO4-p53 senolytic approach]PMID: 34768086DOI: 10.1016/j.ebiom.2021.103693
  4. Kong et al. (2025). FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation [primary; human keloid fibroblast experiments]DOI: 10.1038/s42003-025-07738-0

More questions?

Ask our Support Team — they can answer follow-up questions about this topic, COAs, storage, or anything else in the research library.

Tap the "Chat with us" tab on the right edge of any page.

For research use only. Not medical advice, not therapeutic guidance.

// CONTINUE READING